Biggest News Aggregation in the World
📰 Nasdaq Huma News

Page 4 - Nasdaq Huma News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Huma. Real-time updates on events, politics, business and more.

$260,000.00 in Sales Expected for Humacyte, Inc. (NASDAQ:HUMA) This Quarter

Equities research analysts expect Humacyte, Inc. (NASDAQ:HUMA – Get Rating) to report sales of $260,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Humacyte’s earnings. The lowest sales estimate is $130,000.00 and the highest is $400,000.00. The company is expected to issue its next quarterly earnings report […]
United States Laurae Niklason William John Scheessele Piper Sandler Humacyte Company Profile Get Rating Humacyte Inc

Humacyte (NASDAQ:HUMA) Downgraded by Piper Sandler to "Underweight"

Humacyte (NASDAQ:HUMA – Get Rating) was downgraded by investment analysts at Piper Sandler from an “overweight” rating to an “underweight” rating in a research report issued to clients and investors on Sunday, The Fly reports. Separately, Zacks Investment Research lowered Humacyte from a “buy” rating to a “hold” rating in a research report on Saturday, […]
Piper Sandler Morgan Stanley Humacyte Inc Geode Capital Management Advisor Group Holdings Inc York Capital Management Global Advisors

Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Humacyte (NASDAQ:HUMA – Get Rating) announced its quarterly earnings data on Friday. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.02, MarketWatch Earnings reports. NASDAQ:HUMA opened at $5.37 on Monday. The stock’s fifty day moving average price is $6.60 and its two-hundred day moving average price […]
United States Piper Sandler Penserra Capital Management Zacks Investment Research America Corp Humacyte Inc

Financial Contrast: Humacyte (NASDAQ:HUMA) and Cullinan Oncology (NASDAQ:CGEM)

Humacyte (NASDAQ:HUMA – Get Rating) and Cullinan Oncology (NASDAQ:CGEM – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares Humacyte and Cullinan Oncology’s net margins, […]
New York United States United Kingdom Humacyte Company Profile Get Rating Cullinan Pearl Corp Cullinan Oncology Company Profile Get Rating

Humacyte (NASDAQ:HUMA) Issues Quarterly Earnings Results

Humacyte (NASDAQ:HUMA – Get Rating) issued its quarterly earnings results on Tuesday. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.61, MarketWatch Earnings reports. NASDAQ:HUMA opened at $7.06 on Friday. The business has a 50 day moving average price of $5.76 and a […]
New York United States Thomson Reuter Piper Sandler Penserra Capital Management Zacks Investment Research

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Piper Sandler Lowers Humacyte (NASDAQ:HUMA) Price Target to $10.00

Humacyte (NASDAQ:HUMA – Get Rating) had its target price decreased by equities researchers at Piper Sandler from $17.00 to $10.00 in a research note issued on Tuesday, The Fly reports. Piper Sandler’s price target suggests a potential upside of 37.55% from the stock’s previous close. Separately, Zacks Investment Research upgraded Humacyte from a “hold” rating […]
New York United States Piper Sandler Penserra Capital Management Goldman Sachs Group Inc Virtu Financial

Analysts Anticipate Humacyte, Inc. (NASDAQ:HUMA) to Announce -$0.19 Earnings Per Share

Wall Street analysts expect Humacyte, Inc. (NASDAQ:HUMA – Get Rating) to announce ($0.19) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Humacyte’s earnings. The firm is expected to issue its next earnings results before the market opens on Monday, January 1st. On average, analysts expect […]
New York United States Humacyte Company Profile Get Rating Penserra Capital Management Zacks Investment Research America Corp

Zacks: Analysts Expect Humacyte, Inc. (NASDAQ:HUMA) Will Announce Quarterly Sales of $260,000.00

Wall Street analysts predict that Humacyte, Inc. (NASDAQ:HUMA – Get Rating) will post sales of $260,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Humacyte’s earnings, with the lowest sales estimate coming in at $120,000.00 and the highest estimate coming in at $400,000.00. The firm is scheduled to issue […]
New York United States Geode Capital Management Zacks Investment Research Blackrock Inc Humacyte Inc

Humacyte (NASDAQ:HUMA) Sees Strong Trading Volume

Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Rating) saw strong trading volume on Wednesday . 20,816 shares were traded during trading, a decline of 95% from the previous session’s volume of 411,191 shares.The stock last traded at $5.68 and had previously closed at $5.67. Separately, Zacks Investment Research raised Humacyte from a “hold” rating to […]
New York United States Bradyw Dougan Zacks Investment Research Exos Asset Management Humacyte Company Profile

Analysts Expect Humacyte, Inc. (NASDAQ:HUMA) Will Post Quarterly Sales of $260,000.00

Wall Street brokerages forecast that Humacyte, Inc. (NASDAQ:HUMA – Get Rating) will report sales of $260,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Humacyte’s earnings, with estimates ranging from $120,000.00 to $400,000.00. The business is scheduled to announce its next earnings results on Friday, March 4th. […]
New York United States Laurae Niklason Bradyw Dougan Humacyte Company Profile Get Rating Securities Exchange Commission

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science